In response to the Perspectives pieces published online today by the New England Journal of Medicine, the National Osteoporosis Foundation (NOF) commends the U.S. Food and Drug Administration (FDA) for its continued analysis of long-term bisphosphonate treatment in order to help patients and healthcare providers determine the appropriate length of time for treatment and urges patients not to stop treatment without first talking with their healthcare provider. » Read more
The nation’s top osteoporosis researchers and clinicians will gather in Orlando, Florida this week for the National Osteoporosis Foundation’s (NOF) International Symposium on Osteoporosis (ISO12): Translating Research into Clinical Practice. Held annually, the meeting is the premier scientific event entirely dedicated to the treatment and study of osteoporosis and aims to close the gap between osteoporosis research and its application in clinical practice. As the 2012 recipient of the Lawrence G. Raisz, MD Memorial Lecture Award, Robert Lindsay, M.D., PhD, Chief of Internal Medicine at Helen Hayes Hospital, Past President and long-term NOF Board of Trustees member will present Skeletal Health in Osteoporosis: Past, Present & Future to kickoff the meeting’s opening session at 8:00am on Thursday, April 26. » Read more
The National Osteoporosis Foundation (NOF) named five new members to its Board of Trustees during the International Symposium on Osteoporosis, its annual meeting yesterday. NOF is proud to welcome Franmarie Kennedy; Joan M. Lappe PhD, RN, FAAN; C. Berdon Lawrence; Meryl S. LeBoff, M.D.; and C. Michael Lewiecki, M.D., FACP, FACE, FACP as new trustees. With their diverse backgrounds and experience, NOF is confident its new trustees will help move the organization closer to its goals of better treating osteoporosis for the 44 million Americans currently affected by the disease and preventing osteoporosis for future generations. » Read more
NOF and CMH Summer Adventures invite women across California to attend Using Travel to Jump Start Change: A Conversation with Marybeth Bond. Don’t miss this opportunity to hear directly from Generations of Strength National Honorary Committee member and best-selling author, Marybeth Bond about “what makes life meaningful" and simple ways to contribute to a cause greater than yourself. This women-only event will take place at The General’s Residence, Fort Mason Center, San Francisco, on Tuesday, May 1. Tickets are $10 per person and are available online at http://marybethbond.eventbrite.com.
DXA Not Necessary for Women Under Age 65 and Men Under Age 70 with No Osteoporosis Risk Factors, but Remains Widely Underutilized among those with Highest Fracture Risk » Read more
A new study published this week in the December issue of Health Affairs looked at the impact cuts in Medicare Part B reimbursement have had on access and utilization of DXA testing, the imaging procedure accepted as the gold standard for diagnosing osteoporosis. The study found that after a decade of growth, DXA testing in all Part B settings was stagnant from 2007-2009, resulting in 800,000 fewer tests than expected for Medicare beneficiaries, which if conducted, may have prevented approximately 12,000 fractures.
ORAL REMARKS – NOF President Robert R. Recker - FDA – September 9, 2011
Good afternoon. I am Dr. Robert Recker, director of the Osteoporosis Research Center at Creighton University in Omaha, Nebraska and am here as president of the National Osteoporosis Foundation, the leading consumer and community-focused health organization dedicated to the prevention of osteoporosis and broken bones. » Read more
In this letter, NOF President, Dr. Robert R. Recker, commends the FDA for examining the benefits and risks of long term bisphosphonate use and lays out NOF’s hope that its recommendations will help patients and their healthcare providers better understand the benefits and significant risks of the widely prescribed medications.
In this session, Dr. Khosla will explore the future of osteoporosis therapies including new pathways under investigation and other promising therapeutic agents in development.
Estrogen plays a key role in building and maintaining bone in both men and women. Other sex hormones will be discussed as well to show the different effects each has in the body. It may be possible to use levels of follicle stimulating hormone (FSH) in the blood as a marker to estimate the degree of bone loss during menopause. » Read more
Osteoporosis is a disease characterized by weakened and fragile bone tissue, leading to an increased chance of breaking a bone. The weakened tissue is due to changes in the amount and structure of bone. While people with osteoporosis are most likely to break bones in the spine, hip or wrist, almost any bone can be affected. These bone breaks often occur with minor accidents such as falls, or banging into objects, but can even occur after no accident at all. » Read more
